SCHEMBL25220193

SCHEMBL25220193

O=C(O)c1sc2c(F)c(F)ccc2c1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GRIA4 P48058 1/20 0.38
MAP2 P11137 4/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
TTR P02766 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
LMNA P02545 1/20 0.35
MCL1 Q07820 1/20 0.34
BCKDK O14874 1/20 0.34
DHODH Q02127 1/20 0.34
MAPT P10636 1/20 0.33
PIM1 P11309 1/20 0.33
GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31015920 1.00 CYP2C9 (0.39) CYP2C9CYP2C19GRIA4MAP2KDM4E
SCHEMBL25668191 0.82 GRIA4 (0.37) CYP2C9CYP2C19GRIA4MAP2SMN1; SMN2
SCHEMBL25205779 0.82 HPGD (0.46) CYP2C9CYP2C19KDM4EALDH1A1HPGD
SCHEMBL31015905 0.76 CYP2C9 (0.44) CYP2C9CYP2C19GRIA4KDM4EALDH1A1
SCHEMBL25211130 0.74 CYP2C9 (0.48) CYP2C9CYP2C19GRIA4MAP2KDM4E
SCHEMBL25217782 0.73 BCKDK (0.61) CYP2C9CYP2C19MAP2ALDH1A1LMNA
SCHEMBL69825 0.72 GRIA4 (0.50) CYP2C9CYP2C19GRIA4KDM4EALDH1A1
SCHEMBL2958622 0.70 MCL1 (0.61) CYP2C9CYP2C19GRIA4KDM4EALDH1A1
SCHEMBL25202699 0.70 MCL1 (0.65) CYP2C9CYP2C19MAP2KDM4EALDH1A1
SCHEMBL25228985 0.70 MAP2 (0.48) CYP2C9CYP2C19GRIA4MAP2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466803-B2 BCKDK inhibitors and/or degraders PFIZER INC. (US) 2025-11-11 US disclosed
WO-2023100061-A1 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE PFIZER INC. (US) 2023-06-08 WO disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466803-B2 BCKDK inhibitors and/or degraders BCKDK, KHK, PDK4 CYP2C9 447/4885CYP2C19 668/4885GRIA4 4219/4885
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS BCKDK, KHK, PDK4 CYP2C9 447/4885CYP2C19 668/4885GRIA4 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.